Rituximab therapy for follicular lymphoma: A comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance

Haematologica

Volumn 88, Issue 7, 2003, Pages 811-823

  Cohen, Yossi ^a   Solal Céligny, Philippe ^c   Polliack, Aaron ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Hadassah University Hospital ^*

Author keywords

Autulogous transplantation; Follicular lymphoma; Rituximab; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOLOGICAL ADJUVANT; MITOXANTRONE; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; RITUXIMAB; STEROID;

AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; LEUKEMIA REMISSION; MAINTENANCE THERAPY; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; LYMPHOMA, FOLLICULAR; NEOPLASM RECURRENCE, LOCAL; STEM CELL TRANSPLANTATION;

EID: 0038376702     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Horning S, Rosenberg S. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471-5.
2. Horning S. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
3. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low tumor burden follicular lymphomas between an initial no treatment policy, prednimustine or interferon α: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol 1997;15:1110-7.
4. Hoppe RT, Kushlan P, Kaplan HS, Rosenberg SA, Brown BW. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981;58:592-8.
5. Lucas JB, Tibsharani R, Brophy N, Horning SJ. Follicular lymphoma in young patients: prognostic and survival data from the Stanford series. Blood 1999;94:2307a[abstract].
6. Longo DL, Young RC, Hubbard SM, Wesley M, Fisher RI, Jaffe E, et al. Prolonged remission in patients with nodular mixed lymphoma. Ann Int Med 1984;100:651-6.
7. Glick JH, Barnes JM, Ezdinli EZ, Berard CW, Orlow EL, Bennett JM, et al. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981;58:920-5.
8. Young RC, Longo DL, Glatstein E. The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Semin Hematol 1988;25:11-6.
9. Solal-Céligny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, et al. Doxorubicin-containing regimen with or without interferon α-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998;16:2332-8.
10. Dana BW, Dahlberg S, Nathwani B, Chase E, Coltman C, Miller TP, et al. Long term follow-up of patients with low grade lymphomas treated with doxorubicin based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993;11:644-51.
11. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6.
12. Hochster HS, Kim KM, Green MD, Mann RB, Neiman RS, Oken MM, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992;10:28-32.
13. Solal-Céligny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996;14:514-9.
14. Hochster HS, Oken M, Winter J, Gordon LI, Raphael BG, Bennett JM et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up: a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000;18: 987-94.
15. Hagenbeek A, Eghbali H, Monfardini S, Resegotti E. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stage III and IV low grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients. Blood 1998;10:1294.
16. Klasa R, Shustik C, Sawka C, Smith A, Grenier JF, Berube S. Phase III trial comparing fludarabine to CVP in patients with recurrent low grade, non-Hodgkin's lymphomas. Ann Oncol 1999;10:220[abstract].
17. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262-8.
18. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. (IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
19. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-61.
20. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82.
21. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-7.
22. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000;109:81-8.
23. Case D, Ebrahim JK, Hedlund J, Boyd M, Aronson F, Hayes D. Rituximab in relapsed follicular lymphoma. Blood 1999;94:a [abstract 4704].
24. Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000;79:493-500.
25. Ghielmini M, Schmitz SF, Burki K, Pichert G, Betticher DC, Stupp R, et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000;11 Suppl 1:123-6.
26. Walewski J, Kraszewska E, Mioduszewska O, Romejko-Jarosinska J, Hellmann A, Czyz J, et al. Polish Lymphoma Research Group. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol 2001;18:141-8.
27. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
28. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
29. Hiddemann W, Forstpointner R, Fiedler F, Gramatzki M, Dörken B, Illiger HJ, et al. Combined immuno-chemotherapy (R-FCM) is superior to a Fludarabine-containing regimen (FCM) alone in recurrent follicular and mantel cell lymphomas- results of a prospective randomized comparison of the German Low Grade Study Group (GLSG). ICML 2002;186a[abstract].
30. Herold M, Fiedler F, Pasold R, Knauf W, Freund M, Naumann R, et al. Efficacy and toxicity of rituximab plus MCP versus MCP alone in advanced indolent NHL - interim results of a clinical phase III study of the East German Study Group Hematology/Oncology (OSHO). ICML 2002;511a[abstract].
31. Sacchi S, Tucci A, Merli F, Orsucci L, Cervetti G, Occhini U, et al. Phase II study with fludarabine and cyclophosphamide plus rituximab (FC+R) in relapsed follicular lymphoma patients. Blood 2002;100:2246a[abstract].
32. Weide R, Heymanns J, Pandorf A, Koeppler H. Bendamustine/mitoxantrone/rituximab (BMR): a new effective treatment for refractory or relapsed indolent lymphomas. Blood 2002;100:2247a[abstract].
33. Ogura M, Kikuchi A, Kawase T, Kajimoto K, Kamiya Y, Taji H, et al. Phase I/II study of a new salvage chemotherapy with rituximab (CHASER therapy) for relapsed advanced follicular lymphoma (FL) and mantle cell lymphoma (MCL). Blood 2002;100:4713a[abstract].
34. Amar-Maman D, Mounier N, Manson J, Vignot S, Brice P, Briere J, et al. Evaluation of efficacy and toxicity of rituximab plus aracytin-platinum (R-DHAP) regimen in non-Hodgkin lymphoma (NHL) relapsing patients. Blood 2002;100:4710a [abstract].
35. Komaba S, Tashiro H, Noguchi M, Sanaka T, Gotoh M, Kawasugi K, et al. ESHAP plus RITUXIMAB (ESHAP-R) regimen for relapsing or refractory non-Hodgkin's lymphoma (NHL): study of four cases. Blood 2002;100:a4746[abstract].
36. Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin Cancer Res 2000;7: 2644-52.
37. Bron D, Van Den Neste E, Vandengerghe P, Van Hoof A, Van Droogenbroeck J, De Bock R, et al. Mabthera followed by Roferon induces prolonged responses in patients with refractory/relapsing low grade or follicular lymphomas. A phase II study from the Belgian Hematological Society. ICML 2002; a509[abstract].
38. Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, et al; GISL Clinical activity and safety of combination immunotherapy with IFN-α 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001;86:951-8.
39. Kymby E. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-α2a and granulocyte colony stimulating factor. Semin Oncol 2002;29:2 Suppl 6:7-10.
40. Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117: 828-34.
41. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002;99:67-74.
42. McLaughlin P, Rodriguez MA, Reuben J, East K, Grimm E, Hagemeister FB, et al. Rituximab in combination with GM-CSF (leukine) for patients with recurrent indolent lymphoma. Blood 2001;98:2536a[abstract].
43. Rossi JF, Yang LZ, Quittet P, Navarro R, Legouffe E, Fegueux N, et al. Rituximab (Rab) and GM-CSF, an effective therapy for relapsed/refractory patients (pts) with low-grade B-cell lymphoma (L): correlation between response and dendritic cell (DC) subpopulation mobilized [abstract]. Blood 2001;98: 2542a.
44. TM [Id-KLH] for relapsed indolent non-Hodgkin's lymphoma [abstract]. Blood 2002;99: 1383a.
45. T Hayashi, Kenneth C. Anderson, Steven P. Treon. rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. Blood 2002;100:4800a[abstract].
46. Hegde U, White T, Stetler-Stevenson M, Marti G, Janik J, Pittaluga S, et al. phase I study of combination Rituximab (CD20) and Apolizumab (Hu1D10] monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia. Blood 2002;100:1389a[abstract].
47. Grillo-Lopez AJ. A model for the breadth and depth of clinical effect observed with Rituximab and Zevalin in NHL patients. Blood 2002;100:a4780 [abstract].
48. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7.
49. Solal-Céligny P, Salles G, Brousse P, Soubeyran P, Delwail V, Deconninck E, et al. Updated results of rituximab as single first-line therapy for patients with follicular lymphoma (FL) and a low tumor burden: clinical and molecular evaluation. ICML 2002;a506[abstract].
50. Witzig TE, Vukov AM, Habermann TM, Geyer S, Friedenberg WR, White WL, et al. Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): a phase II trial in the North Central Cancer Treatment Group (NCCTG). Blood 2002;100: a1398[abstract].
51. Ferrari D, Girmenia G, Brunati S, Rosato E, Montillo M. Successful response to rituximab as a single agent in bulky disease follicular lymphoma. Blood 2002;100:a4783[abstract].
52. Emmanouilides CR. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002;17:621-30.
53. Czuczman M, Fallon A, Mohr A, Carleton S, Bernstein ZP, McCARTHNY p, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29 Suppl 2:36-40.
54. Maloney DG, Press OW, Braziel RM, Unger JM, LeBlanc ML, Grogan TM, et al. A phase II Trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. Blood 2001;98:a3502[abstract].
55. Jaeger G, Neumeister P, Brezinschek R, Hofler G, Quehenberger F, Linkesch W, Sill H. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol 2002;69:21-6.
56. Zinzani PL, on Behalf of an Italian Cooperative Study Group on Lymphoma. A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL). Blood 2001;98:a344[abstract].
57. Czuczman MS, Fallon A, Mohr A, Stewart C, Klippenstein D, Loud P, et al. Phase II Study of Rituximab Plus Fludarabine in Patients (pts) with Low-Grade Lymphoma (LGL): Final Report. Blood 2001;98a2518[abstract].
58. Vitolo U, Boccomini C, Astolfi M, Ladetto M, Rota-Scalbrini D, Pogliani E, et al. High clinical and molecular response rate in elderly patients with advanced stage follicular lymhoma treated at diagnosis with a brief chemo-immunotherapy FND + rituximab. Blood 2002;98:a1392[abstract].
59. Cohen A, Polliack A, Ben-Bassat I, Avigdor A, Bennett M, Berkowicz M, et al. Results of a phase ii study employing a combination of fludarabine, cyclophosphamide and Rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL): The Israel Cooperative Lymphoma Group. Blood 2002;100a1393[abstract].
60. Gregory SA, Venugopal P, Adler S, Enschede S, Yunus F, O'Brien T, et al. Combined fludarabine, mitoxantrone, and Rituximab achieves a high response as initial treatment for advanced low grade non-hodgkin's lymphoma (LGNHL). Blood 2002;100a 1401 [abstract].
61. Rubio-Borja ME, Tripp FJ, Baez E, Rivas S, Rubio B, Baltasar S. CNOP vs CNOP-R vs Ruximab monotherapy as first-line therapy for indolent non-Hodgkin lymphoma (I NHL). A preliminary report from the Mexican Multicentric Hematology Study Group. Blood 2002;100:a4794[abstract].
62. Odaimi M, Rubin A, Ahern K, Lee R, Basile M, Terjanian T, et al. Interim results of a phase II trial of therapy with cyclophosphamide/pentostatin/Rituximab for indolent NHL and CLL. Blood 2002;100:a4797[abstract].
63. Martinelli G, Laszlo D, Mancuso P, Santoro P, Pruneri G, Vanazzi A, et al. Rituximab plus chlorambucil in low-grade non Hodgkin's lymphomas (NHL): clinical results of a phase II study. Blood 2002;100:a3073[abstract].
64. Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, et al. IDEC-C2B8 Study Group. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73:213-21.
65. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000;18:3135-43.
66. Coiffier B, Bouaffia F, Thieblemont C, Hequet O, Arnaud P, Dumontet C, et al. Rituximab re-treatment in B-cell lymphoma patients: efficacy and toxicity in 59 patients treated in one center. Blood 2002;100:a1390[abstract].
67. Cohen Y, Libster D, Da'as D, Amir G, Polliack A. Re-treatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab. The Hematology Journal 2003;4:151-3.
68. Ghielmini M, Schmitz SFH, Cogliatti S, Pichert G, Fey M, Betticher D, et al. Lymphoma Working Group, Swiss Group for Clinical Cancer Research (SAKK). Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial. Blood 2002;100:a604[abstract].
69. Gordan L, Grow WB, Braylan RC, Mendenhall NP, Douglas V, Pusateri A, et al. A phase II trial of individualized pharmacokinetic dosing of rituximab maintenance for patients with CD20 positive lymphoproliferative disorders. Blood 2002;100: a1400[abstract].
70. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;4:344:68-9.
71. Schmitz K, Brugger W, Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999;106:571-2.
72. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 2000;6:317-8.
73. Leo E, Scheuer L, Kraemer A, Kerowgan M, Leo A, Anthony D. Unexpected hematotoxicity associated with a combination of Rituximab, fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Blood 2002;100:a4745 [abstract].
74. Jilani I, O'Brien S, Manshouri T, Thomas DA, Thomazy VA, Imam M, et al. Transient Downmodulation of CD20 by rituximab. Blood 2002;100:a3174[abstract].
75. Seliem RM, Freeman JK, Hasserjian RP. Modulation of CD20 expression in B-cell lymphomas treated with Rituximab. Blood 2002;100:a4787[abstract].
76. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Grimmett K, Gill D. Incidence and nature of CD20 negative relapses following Rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Blood 2002;100:a1394 [abstract].
77. Savage KJ, Weng AP, Kutok JL, Pinkus G, Gribben JG. Loss of CD20 expression following treatment with anti-CD20 monoclonal antibody in chronic lymphocytic leukemia. Blood 2002;100:a5013[abstract].
78. Cohen Y, Da'as N, Libster D, Amir G, Berrebi A, Polliack A. Large cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab containing regimens: natural history or therapy related complication? Eur J Haematol 2002;68:1-9.
79. Finke J, Slanina J, Lange W, Dolken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol 1994;12:798-805.
80. Price CG, Meerabux J, Murtagh S, Cotter FE, Rohatiner AZ, Young BD, et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 1993;11:1668-73.
81. Lambrechts AC, Hupkes PE, Dorssers LC, van't Veer MB. Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 1994;12:1541-6.
82. Mandigers CM, Meijerink JP, Mensink EJ, Tonnissen EL, Hebeda KM, Bogman MJ, et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 2001 15;98:940-4.
83. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-62.
84. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-33.
85. Hirt C, Dolken G. Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant 2000;25:419-26.
86. Zwicky C, Maddocks A, Andersen N, Gribben J. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996;88:3314-22.
87. Salles G, Coiffier B. Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Baillieres Best Pract Res Clin Haematol 1999;12:151-69.
88. Johnson PW, Price CG, Smith T, Cotter FE, Meerabux J, Rohatiner AZ, et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994;12:1685-92.
89. Ladetto M, Volpato F, Drandi D, Compagno M, Astolfi M, Mantoan B, Vallet S, Ricca I, Corradini P, Boccadoro M, Tarella C. Frequent detection of rearrangements unrelated to those observed at diagnosis in late molecular recurrences of follicular lymphoma (FL) patients. Blood 2002;100:a2220[abstract].
90. Sarris AH, Jiang Y, Tsimberidou AM, Thomaides A, Rassidakis GZ, Ford RJ, et al. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol 2002;291Suppl 2:48-55.
91. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001;97:404-9.
92. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-33.
93. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002;100:1559-65.
94. Martin S, Fischer C, Niederste-Hollenberg A, Free M, Meckenstock G, Haas R, et al. Eradication of minimal residual disease in patients with follicular lymphoma depends on the disease status and the type of cytotoxic therapy combined with the anti-CD20 monoclonal antibody (rituximab) as revealed by molecular monitoring with nested and real-time PCR. Blood 2002;100:a1395[abstract].
95. Emmanouilides C, Lill M, Rosenfelt F, Abdelkedous S, Telatar M, Grody W, et al. Mine-Rituxan salvage and in vivo purging in patients with lymphoma. Blood 2001;98:abstract3077 [abstract].
96. Buckstein RJ, Imrie KR, Spaner D, Mangel J, Tompkins K, Crump M, et al. Autologous stem cell transplants combined with rituximab for relapsed follicular lymphoma achieve prolonged clinical and molecular remissions. Blood 2001;98:a2846 [abstract].
97. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001;15:1941-9.
98. Buckstein RJ, Rimrie K, Pennell N, Spaner D, Hewitt K, Berinstein NL. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab. Leuk Lymphoma 2001;41:451-5.
99. Flinn IW, Jones RJ, Goodrich A, Carter-Brookins D, Moss TJ, Loper K, et al. Rituximab during autologous stem cell transplantion for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays. Blood 2001;98:a2832 abstract.
100. Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002;29:769-75.
101. Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002;116:229-35.
102. Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as in vivo purge and consolidative immunotherapy following autologous stem cell transplantation. Blood 2002;100:a5498 [abstract].
103. Leonard JP, Coleman M, Matthews JC, Dosik A, Fiore JM, Kapushok H, et al. High complete response rate following Epratuzumab (anti CD22) and rituximab (anti CD-20) combination antibody therapy in follicular non-Hodgkins lymphoma (NHL). ICML 2002;a111[abstract].
104. Ladetto M, Ricca I, Benedetti F, Vitolo U, Liberati M, Musso M, et al. Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: an interim analysis. Blood 2002;100:a4769 [abstract].
105. Brugger W, Hirsch J, Repp R, Grünebach F, Schlimok G, Vogel W, et al. Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation: a multicenter phase ii study. Blood 2002;100:a2532[abstract].
106. Buckstein RJ, Mangel J, Imrie K, Spaner D, Crump M, Pennell N, et al. High dose therapy/ASCT consolidated with rituximab and or α interferon immunotherapy for relapsed follicular lymphoma prolongs PFS and achieves durable molecular remissions. Blood 2002;100:a2547[abstract].
107. Blum KA, Hidalgo J, Khoury H, Baty J, Brown RA, Adkins DR, et al. Delayed neutrophil and platelet engraftment following autologous transplantation in non-Hodgkins lymphoma patients previously treated with rituximab. Blood 2002;100: a2531[abstract].
108. Hidalgo KA, Blum KA, Adkins D, Brown R, Devine S, Mayfield J, et al. Impact of pre-transplant rituximab on early posttransplant complications in NHL. Blood 2002;100:a5313 [abstract].
109. Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999;26:Suppl 14:115-22.
110. Buckstein PJ, Mangel J, Imrie KR, Spaner D, Boudreau A, Crump M, et al. Immunoglobulin recovery following high dose therapy and post-ASCT rituximab for relapsed follicular lymphoma (FL) and newly diagnosed mantle cell lymphoma (MCL) compared to standard dose chemotherapy. Blood 2002;100: a5502[abstract].
111. Dillman RO, Chico S. Low-grade lymphomas: comparison of histologic classifications and survival rates for patients diagnosed during the last two decades. Blood 2002;100:a4631 [abstract].
112. Hirt C, Schueler F, Schwenke C, Kiefer T, Herold M, Dolken G. High percentage of molecular remissions in advanced stage follicular lymphoma (FL) patients treated with chemoimmunotherapy in comparison to chemotherapy alone. Blood 2002;100:a1402[abstract].